Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Managing MM patients through multiple lines of therapy: risk vs benefit

Joshua Richter • 7 Jul 2020
EHA 2020
Multiple Myeloma

Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, discusses the use of multiple lines of therapy in patients with multiple myeloma and the impact on patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Joshua Richter

1:33
Updates from the LINKER-MM1 study: linvoseltamab in R/R multiple myeloma
Joshua Richter • 27 Sep 2023
1:14
Prevention & monitoring of infections in patients with multiple myeloma treated with immunotherapies
Joshua Richter • 27 Sep 2023
1:44
Matching-adjusted indirect comparison of Isa-Kd versus Dara-Rd in relapsed multiple myeloma
Joshua Richter • 27 Sep 2023
1:45
The value of teclistamab in R/R myeloma & strategies to mitigate toxicities
Joshua Richter • 27 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals